# Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma

> **NCT04080154** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04080154
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-24
- **Primary completion:** 2021-02
- **Final completion:** 2021-10
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04080154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04080154, "Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04080154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*